// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Discrepant Interpretation of HIT Screening Results on the Same Sample – Data from a UK NEQAS for Blood Coagulation Exercise

I. Jennings - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Distribution of Hemophilia A and B within the INSIGHT Consortium

A.-F. Zwagemaker - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Does the von Willebrand Factor: ADAMTS-13 Axis Differ between Antiphospholipid Syndrome and Systemic Lupus Erythematosus?

M.N. Dang - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Dynamic Changes in Peripheral Blood Transcriptome Profiles May Predict Inhibitor Formation in Previously Untreated Patients with Severe Hemophilia A

P. Batty - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

simoctocog alfa

Dysfunctional RBM8A/Y14 Does Not Impair Megakaryopoiesis but Terminal Thrombopoiesis in Thrombocytopenia Absent Radii (TAR) Syndrome

G. Manukjan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombocytopenia-absent radius syndrome

N/A

Early Physiotherapy Intervention Reduces the Long Term Effects of Venous Thromboembolism and Promotes an Improved Quality of Life: Results from a Pilot Study

R. Lewis - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Edoxaban Treatment of Venous Thromboembolism in Routine Clinical Practice in the Non-Interventional Global ETNA-VTE Program: A Sub-Analysis by Age Groups

G. Agnelli - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Edoxaban

Effects of Anticoagulants on Fibrin Clot Structure: A Comparison between Vitamin K Antagonists and FXa inhibitors

J. S. Gauer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Effects of Body Mass Index on the Human Plasma Proteome – Potential Drivers of Obesity-related Cardiovascular Disease?

L. Goudswaard - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Effects of GPVI on Clot Structure: Reduction in Procoagulant Platelets in GPVI-Deficient Clots

J. S. Gauer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Effects of Rivaroxaban on Thrombophilia Screening Tests – Results from a UK NEQAS (Blood Coagulation) Exercise

I. Jennings - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Effects of the Bacterial Toxin Cytotoxic Necrotising Factor 1 on Platelet Function

A. Chacko - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients Aged from Birth to < 2 Years - Results of the DIVERSITY Trial

J. Halton - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Efficacy and Target Joint Resolution with Pharmacokinetic-Guided Rurioctocog Alfa Pegol Prophylaxis Targeting Two Factor VIII trough Levels in Patients with Severe Hemophilia A: Post-Hoc Analysis of the Phase 3 PROPEL Trial

P. Collins - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

rurioctocog alfa

Elevated D-dimers Useful Prediction of Pulmonary Artery Thrombosis in COVID-19 Patients at Initial Presentation to Hospital

A. Perera - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Emicizumab Concentration in Children: A Single Centre Real World Experience

D. Gosrani - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

ETNA VTE Europe: A Contemporary Snapshot of VTE Patients Treated with Edoxaban in Clinical Practice across Eight European Countries

A.T. Cohen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Edoxaban

ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban

M. Schindewolf - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Edoxaban

ETNA-VTE Global: Evaluation of Bleeding Risk Based on VTE-BLEED Score on 12-month Outcomes in a Population Treated with Edoxaban

A. Cohen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Edoxaban

Evaluation of a Rapid, Automated Chemiluminescent ADAMTS-13 Activity Assay for the ACL AcuStar

R.E. Fretwell - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved